GENSCRIPT BIO Announces Legend Biotech’s Q1 2026 Results Filing with U.S. SEC

Bulletin Express

May 12

Genscript Biotech Corporation (GENSCRIPT BIO) has issued a voluntary announcement noting that its Nasdaq-listed associate, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission on 12 May 2026. The filing covers Legend Biotech’s financial results and business highlights for the quarter ended 31 March 2026.

The disclosure clarifies that the reported figures relate solely to Legend Biotech and do not reflect GENSCRIPT BIO’s standalone performance. Shareholders and prospective investors are urged to consider the distinct financial profiles of the two entities and exercise caution when dealing in GENSCRIPT BIO securities.

The Board of GENSCRIPT BIO, chaired by Executive Director Mr. Robin Meng, emphasised that the announcement serves purely as an informational update. Further details of Legend Biotech’s quarterly performance can be accessed through the SEC’s website using the reference link provided in the Form 6-K filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1191568096"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191568096\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1191568096?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191568096","market":"hk","top_or_hot":-1,"title":"GENSCRIPT BIO Announces Legend Biotech’s Q1 2026 Results Filing with U.S. SEC","media":"Bulletin Express","content":"<p>Genscript Biotech Corporation (GENSCRIPT BIO) has issued a voluntary announcement noting that its Nasdaq-listed associate, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission on 12 May 2026. The filing covers Legend Biotech’s financial results and business highlights for the quarter ended 31 March 2026.</p>\n<p>The disclosure clarifies that the reported figures relate solely to Legend Biotech and do not reflect GENSCRIPT BIO’s standalone performance. Shareholders and prospective investors are urged to consider the distinct financial profiles of the two entities and exercise caution when dealing in GENSCRIPT BIO securities.</p>\n<p>The Board of GENSCRIPT BIO, chaired by Executive Director Mr. Robin Meng, emphasised that the announcement serves purely as an informational update. Further details of Legend Biotech’s quarterly performance can be accessed through the SEC’s website using the reference link provided in the Form 6-K filing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENSCRIPT BIO Announces Legend Biotech’s Q1 2026 Results Filing with U.S. SEC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENSCRIPT BIO Announces Legend Biotech’s Q1 2026 Results Filing with U.S. SEC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-12 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genscript Biotech Corporation (GENSCRIPT BIO) has issued a voluntary announcement noting that its Nasdaq-listed associate, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission on 12 May 2026. The filing covers Legend Biotech’s financial results and business highlights for the quarter ended 31 March 2026.</p>\n<p>The disclosure clarifies that the reported figures relate solely to Legend Biotech and do not reflect GENSCRIPT BIO’s standalone performance. Shareholders and prospective investors are urged to consider the distinct financial profiles of the two entities and exercise caution when dealing in GENSCRIPT BIO securities.</p>\n<p>The Board of GENSCRIPT BIO, chaired by Executive Director Mr. Robin Meng, emphasised that the announcement serves purely as an informational update. Further details of Legend Biotech’s quarterly performance can be accessed through the SEC’s website using the reference link provided in the Form 6-K filing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1191568096","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191568096","pubTimestamp":1778586213,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Genscript Biotech Corporation (GENSCRIPT BIO) has issued a voluntary announcement noting that its Nasdaq-listed associate, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"金斯瑞生物宣布传奇生物向美国SEC提交2026年第一季度业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"Genscript Biotech Corporation (GENSCRIPT BIO) has issued a voluntary announcement noting that its Nasdaq-listed associate, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission on 12 May 2026. The filing covers Legend Biotech’s financial results and business highlights for the quarter ended 31 March 2026.\nThe disclosure clarifies that the reported figures relate solely to Legend Biotech and do not reflect GENSCRIPT BIO’s standalone performance. Shareholders and prospective investors are urged to consider the distinct financial profiles of the two entities and exercise caution when dealing in GENSCRIPT BIO securities.\nThe Board of GENSCRIPT BIO, chaired by Executive Director Mr. Robin Meng, emphasised that the announcement serves purely as an informational update. Further details of Legend Biotech’s quarterly performance can be accessed through the SEC’s website using the reference link provided in the Form 6-K filing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}